Lobbying disclosures · Lobbying report
CL: third_quarter 2026 lobbying report
FDA and HHS engagement regarding oral health, medical research, issues related to the contents and manufacturing of oral care products FDA and HHS engagement regarding oral health, medical research, issues related to the contents and manufacturing of oral care products FDA and HHS engagement regarding oral health, medical research, issues related to the contents and manufacturing of oral care products
Follow CL- Became public
- Oct 17, 2026, 8:49 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 5:49 AM EST
Why this is connected
Legal-name match: COLGATE-PALMOLIVE COMPANY is COLGATE PALMOLIVE CO (https://www.sec.gov/Archives/edgar/data/21665/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $50,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/365fea78-acaa-46c5-b7f6-74cb8a3e4afc/","filing_uuid":"365fea78-acaa-46c5-b7f6-74cb8a3e4afc","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/365fea78-acaa-46c5-b7f6-74cb8a3e4afc/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Alisa Hess","dt_posted":"2026-10-17T20:49:32-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 North Capitol Street, NW","registrant_address_2":"Suite 210","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":1171,"url":"https://lda.gov/api/v1/registrants/1171/","house_registrant_id":31749,"name":"ALPINE GROUP PARTNERS, LLC.","description":"Public relations consulting firm","address_1":"500 North Capitol Street, NW","address_2":"Suite 210","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ALISA JANE HESS","contact_telephone":"+1 434-933-2535","dt_updated":"2026-08-19T14:46:16.762025-04:00"},"client":{"id":69625,"url":"https://lda.gov/api/v1/clients/69625/","client_id":69625,"name":"COLGATE-PALMOLIVE COMPANY","general_description":"A consumer and household products company","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-10-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FDA and HHS engagement regarding oral health, medical research, issues related to the contents and manufacturing of oral care products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149082,"prefix":null,"prefix_display":null,"first_name":"COLIN","nickname":null,"middle_name":null,"last_name":"BRAINARD","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Steve Watkins; Executive Director, Joint Economic Cmte.; Dep. Chief of Staff, Rep. Erik Paulsen; Dep. Chief of Staff, Rep. Lynn Jenkins; LC, Sen. Richard Burr","new":false},{"lobbyist":{"id":139167,"prefix":"mr","prefix_display":"MR.","first_name":"GREG","nickname":null,"middle_name":null,"last_name":"WALDEN","suffix":null,"suffix_display":null},"covered_position":"US Congressman 1999-2021","new":false},{"lobbyist":{"id":145638,"prefix":null,"prefix_display":null,"first_name":"SHAYNE","nickname":null,"middle_name":null,"last_name":"WOODS","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant, Sen. Tim Scott; Senior Policy Advisor, Rep.Gus Bilirakis","new":false},{"lobbyist":{"id":150052,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":"LD, Rep. Anna Eshoo; Congressional Liaison - FDA","new":false},{"lobbyist":{"id":140067,"prefix":null,"prefix_display":null,"first_name":"HANNAH","nickname":null,"middle_name":null,"last_name":"SCHMIDT","suffix":null,"suffix_display":null},"covered_position":"Professional Staff, House Small Business Cmte","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"FDA and HHS engagement regarding oral health, medical research, issues related to the contents and manufacturing of oral care products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140067,"prefix":null,"prefix_display":null,"first_name":"HANNAH","nickname":null,"middle_name":null,"last_name":"SCHMIDT","suffix":null,"suffix_display":null},"covered_position":"Professional Staff, House Small Business Cmte","new":false},{"lobbyist":{"id":150052,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":"LD, Rep. Anna Eshoo; Congressional Liaison - FDA","new":false},{"lobbyist":{"id":145638,"prefix":null,"prefix_display":null,"first_name":"SHAYNE","nickname":null,"middle_name":null,"last_name":"WOODS","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant, Sen. Tim Scott; Senior Policy Advisor, Rep.Gus Bilirakis","new":false},{"lobbyist":{"id":139167,"prefix":"mr","prefix_display":"MR.","first_name":"GREG","nickname":null,"middle_name":null,"last_name":"WALDEN","suffix":null,"suffix_display":null},"covered_position":"US Congressman 1999-2021","new":false},{"lobbyist":{"id":149082,"prefix":null,"prefix_display":null,"first_name":"COLIN","nickname":null,"middle_name":null,"last_name":"BRAINARD","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Steve Watkins; Executive Director, Joint Economic Cmte.; Dep. Chief of Staff, Rep. Erik Paulsen; Dep. Chief of Staff, Rep. Lynn Jenkins; LC, Sen. Richard Burr","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"FDA and HHS engagement regarding oral health, medical research, issues related to the contents and manufacturing of oral care products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140067,"prefix":null,"prefix_display":null,"first_name":"HANNAH","nickname":null,"middle_name":null,"last_name":"SCHMIDT","suffix":null,"suffix_display":null},"covered_position":"Professional Staff, House Small Business Cmte","new":false},{"lobbyist":{"id":149082,"prefix":null,"prefix_display":null,"first_name":"COLIN","nickname":null,"middle_name":null,"last_name":"BRAINARD","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Steve Watkins; Executive Director, Joint Economic Cmte.; Dep. Chief of Staff, Rep. Erik Paulsen; Dep. Chief of Staff, Rep. Lynn Jenkins; LC, Sen. Richard Burr","new":false},{"lobbyist":{"id":139167,"prefix":"mr","prefix_display":"MR.","first_name":"GREG","nickname":null,"middle_name":null,"last_name":"WALDEN","suffix":null,"suffix_display":null},"covered_position":"US Congressman 1999-2021","new":false},{"lobbyist":{"id":145638,"prefix":null,"prefix_display":null,"first_name":"SHAYNE","nickname":null,"middle_name":null,"last_name":"WOODS","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant, Sen. Tim Scott; Senior Policy Advisor, Rep.Gus Bilirakis","new":false},{"lobbyist":{"id":150052,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":"LD, Rep. Anna Eshoo; Congressional Liaison - FDA","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in CL
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Colgate-Palmolive Company CL
$1K–$15K · Traded Sep 25, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Colgate-Palmolive Company CL
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Sep 25, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
Sold (partial) Colgate-Palmolive Company CL
$1K–$15K · Traded Sep 2, 2026 · disclosed Sep 25, 2026 · Joint
- Sep 25, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
Sold Colgate-Palmolive Company CL
$1K–$15K · Traded Aug 31, 2026 · disclosed Sep 25, 2026
- Sep 25, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
Sold (partial) Colgate-Palmolive Company CL
$1K–$15K · Traded Aug 27, 2026 · disclosed Sep 25, 2026
- Sep 1, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
Sold Colgate-Palmolive Company CL
$1K–$15K · Traded Aug 19, 2026 · disclosed Sep 1, 2026 · Joint
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
Sold Colgate-Palmolive Company CL
$1K–$15K · Traded Sep 23, 2025 · disclosed Aug 5, 2026 · Joint · filed 316 days later
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
Bought Colgate-Palmolive Company CL
$1K–$15K · Traded Sep 23, 2025 · disclosed Aug 5, 2026 · Joint · filed 316 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.